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ABSTRACT
Pseudoxanthoma elasticum (PXE) and generalized arterial calcification of infancy
(GACI) are heritable disorders manifesting with ectopic tissue mineralization. Most
cases of PXE and some cases of GACI are caused by mutations in the ABCC6 gene,
resulting in reduced plasma pyrophosphate (PPi) levels. There is no effective treatment
for these disorders. It has been suggested that administration of bisphosphonates,
stable and non-hydrolyzable PPi analogs, could counteract ectopic mineralization
in these disorders. In this study we tested the potential efficacy of etidronate, a
first generation bisphosphonate, on ectopic mineralization in the muzzle skin of
Abcc6-/- mice, a model of PXE. The Abcc6-/- mice received subcutaneous injections of
etidronate, 0.283 and 3.40 mg/kg per injection (0.01× and 0.12×), twice a week, in
both prevention and reversal studies. Ectopic mineralization in the dermal sheath of
vibrissae in muzzle skin was determined by histopathologic analysis and by direct
chemical assay for calcium content. Subcutaneous injection of etidronate prevented
ectopic mineralization but did not reverse existing mineralization. The effect of
etidronate was accompanied by alterations in the trabecular bone microarchitecture,
determined by micro-computed tomography. The results suggest that etidronate may
offer a potential treatment modality for PXE and GACI caused by ABCC6 mutations.
Etidronate therapy should be initiated in PXE patients as soon as the diagnosis is
made, with careful monitoring of potential side effects.

INTRODUCTION

during fetal development [3, 4]. ABCC6 encodes a
transmembrane efflux transporter, ABCC6, expressed
primarily in the liver, to a lesser extent in the kidneys, and
at very low levels, if at all, in tissues subject to ectopic
mineralization [5, 6]. These observations, together with
results from animal studies, have suggested that PXE
is a metabolic disorder deficient in circulating factor(s)
required physiologically to prevent ectopic mineralization
[7, 8]. While the precise physiologic function of ABCC6
is currently unclear, recent studies have indicated that
ABCC6 is required for release of ATP from hepatocytes
to the extracellular milieu where it is readily converted
enzymatically to inorganic pyrophosphate (PPi) and AMP

Pseudoxanthoma elasticum (PXE), an autosomal
recessive genodermatosis, is characterized by ectopic
deposition of calcium hydroxyapatite in the skin, eyes, and
the cardiovascular system, with considerable morbidity
and occasional early mortality (For review see [1, 2]).
The majority of cases with the classic form of PXE result
from biallelic inactivating mutations in the ABCC6 gene.
ABCC6 mutations can also cause generalized arterial
calcification of infancy (GACI), another autosomal
recessive disorder characterized by severe ectopic
mineralization of the cardiovascular system that begins
www.oncotarget.com
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by ectonucleotide pyrophosphatase/phosphodiesterase 1
(ENPP1), an enzyme encoded by ENPP1 [9, 10]. Since
PPi is physiologically a powerful anti-mineralization
factor and proper PPi/Pi ratio in circulation is required to
prevent ectopic mineralization, loss-of-function mutations
in ABCC6 result in a reduced extracellular concentration
of ATP and lowered PPi/Pi ratio, which then allow ectopic
mineralization to ensue in patients with PXE.
There is currently no effective or specific treatment
for PXE. The observations of reduced plasma PPi levels in
PXE have led to the suggestion that administration of PPi
would encounter ectopic mineralization, but unfortunately,
PPi is unstable with relatively short half-life in circulation
[11]. Recent studies have suggested, however, that
administration of stable PPi analogs, bisphosphonates,
could be used for treatment of ectopic mineralization
disorders [12]. Bisphosphonates are structural analogs of
PPi in which the oxygen linkage between phosphonate
(PO3) groups is replaced by a carbon. Bisphosphonates
also have two side groups (R1, R2), and different
substitutions at these side chains alter their pharmacologic
characteristics, specificity and relative potency [13, 14].
Bisphosphonates have two principal modes of action on
mineral metabolism: (a) They can display physicochemical
anti-mineralization properties that inhibit through
their ability to limit the growth of mineral crystals,
and (b) they exhibit biochemical properties that enable
them to inhibit osteoclast activity. The latter property
is the premise of their use in treatment of conditions
characterized by bone loss, particularly osteoporosis [15].
Different bisphosphonates have various degrees of antimineralization and anti-osteoclastic activities. The first
generation bisphosphonates, such as etidronate (ETD),
a non-nitrogen containing bisphosphonate, displays
considerable anti-mineralization activity, but is a relatively
low-potency inhibitor of osteoclasts. By contrast, the
third generation, nitrogen-containing bisphosphonates, as
exemplified by alendronate (AST), are significantly more
potent inhibitors of osteoclasts than the non-nitrogen
containing ones, but the low doses required for this
effect preclude administration of these drugs in quantities
sufficient to exert significant inhibition of mineralization.
We recently initiated studies to explore the potential
of bisphosphonates for treatment of ectopic mineralization
disorders by administration of ETD or AST to genetically
engineered mutant mice depicting extensive cutaneous
and vascular mineral deposits. In one set of studies, these
bisphosphonates were administered orally or by subcutaneous
injections to Enpp1asj mice, a model for GACI, a severe
disorder in which the patients often die within the first year
of life from complications of vascular calcification [16]. The
results suggested that these two bisphosphonates, particularly
ETD, were capable of preventing ectopic mineralization in
the dermal sheath of vibrissae and in the aorta. Furthermore,
preliminary studies using a mouse model for PXE,
the Abcc6tm1JfK mice (referred hereon as Abcc6-/- mice),
www.oncotarget.com

demonstrated that feeding of ETD reduced mineralization
at the early stages of the process [17]. However, relatively
high doses of ETD were needed, probably due to the fact
that absorption of ETD from the gastrointestinal track is
poor, typically 1% or less [14]. Furthermore, these studies
did not address the question of whether bisphosphonates are
capable of reversing the ectopic mineralization by enhancing
resorption of pre-existing calcium hydroxyapatite.
The Abcc6-/- mice have been shown to have
markedly reduced PPi/Pi plasma ratio due to decreased PPi
levels but normal Pi and calcium serum concentrations.
[9, and Li et al., unpublished]. In this study, we have
tested the efficacy of ETD in both preventing the ectopic
mineralization process and in potentially reversing the
existing calcification by subcutaneous injection of ETD
into Abcc6 knockout mice.

RESULTS
Experimental design
The Abcc6-/- mouse recapitulates features of PXE
by developing late onset (5–6 weeks of age) and slowly
progressing mineralization of the dermal sheath of
vibrissae in the skin, Bruch’s membrane in the eye, and
in the arterial blood vessels of the cardiovascular system
[18]. The first site of mineralization is the dermal sheath
of vibrissae, a connective tissue capsule surrounding
the sinus adjacent to the hair bulb of vibrissae. We have
previously shown that the mineralization of this dermal
sheath is progressive and reflects the mineralization of
arterial blood vessels, thus allowing us to monitor the
temporal degree of mineralization in this mouse model
by histopathology or direct chemical assay of calcium
in biopsies of muzzle skin or by non-invasive microcomputed tomography (µCT) [19, 20].
In this study, two sets of experimental design
were utilized to test the efficacy of ETD. In the first set
of experiments (Set 1), the Prevention Study, Abcc6-/mice were treated with ETD by subcutaneous injections
twice per week, initiated at weaning at 4 weeks of age,
i.e., before mineralization develops, and continued for
another 8 weeks. This experiment allowed us to determine
whether ETD can prevent ectopic mineral deposition in
these mice. The second set of experiments (Set 2), the
Reversal Study, allowed the mice to grow up to 12 weeks
of age, i.e., the age at which clearly detectable ectopic
mineralization is present. The mice were then subjected
to ETD administration by subcutaneous injections for
another 12 weeks. In both sets of experiments, two doses
of ETD were used, 0.283 and 3.40 mg per kg of body
weight per injection; these concentrations correspond to 1
percent (0.01×) and 12 percent (0.12×) of the typical oral
dose used for treatment of osteoporosis in adult human
patients (8 mg/kg/day assuming 50 kg body weight; http://
www.rxlist.com/didronel-drug.htm). For proper amount of
30722
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Table 1: Experimental groups of Abcc6-/- mice by genotype and treatment*
Group, injected with

No. of mice examined
(M+F)

Genotype

Treatment started >
treatment ended (weeks)

Prevention Study (Set 1):
saline
7 (3+4)
4 > 12
Abcc6-/4 > 12
0.01× ETD
10 (5+5)
Abcc6-/-/4 > 12
0.12× ETD
10 (6+4)
Abcc6
-/4 > 12
NT
10 (5+5)
Abcc6
Reversal Study (Set 2):
10 (5+5)
saline
12 > 24
Abcc6-/-/10 (5+5)
12 > 24
0.01× ETD
Abcc6
-/10 (5+5)
12 > 24
0.12× ETD
Abcc6
-/10 (5+5)
12 > 24
NT
Abcc6
10 (5+5)
12 > 24
NT
Abcc6+/+
*
All the mice were placed on control diet at 4 weeks of age post-weaning. In Prevention Study, the mice at 4 weeks of
age were injected subcutaneously with saline, 0.01× ETD or 0.12× ETD, for an additional 8 weeks. Mineralization was
determined at 12 weeks of age. In Reversal Study, the Abcc6-/- mice were allowed to develop mineralization up to 12 weeks
of age and they were then injected and followed for an additional 12 weeks. At this point, at 24 weeks of age, the mice were
euthanized for analysis. ETD, etidronate; M, male; F, female; NT, not treated.

Etidronate does not reverse the existing ectopic
mineralization in Abcc6-/- mice

ETD to be injected, the mice were weighed every week,
and the dose was adjusted accordingly per g body weight.
In both experiments, mice were treated in parallel with
saline injections. Each group consisted of 7–10 mice,
with approximately equal distribution between males and
females (Table 1).
At the end of each experiment, the mice were
sacrificed, and the degree of mineralization in the dermal
sheath of vibrissae was determined semi-quantitatively
by staining tissue sections with Alizarin red or by direct
chemical assay of calcium content in the biopsies of
muzzle skin containing the dermal sheath of vibrissae.
Since ETD is known to affect the morphology of long
bones, the femurs of these mice were examined separately
in male and female mice by µCT.

Examination of the dermal sheath of vibrissae of
the Abcc6-/- mice that were untreated controls or were
injected with saline at 24 weeks of life demonstrated
progressive mineralization as compared to mice at 12
weeks of age (Figures 1 and 2). Injection of ETD, 0.01× or
0.12× between 12 and 24 weeks of age, resulted in lower
level of mineralization than in mice injected with saline.
However, the degree of mineralization, as quantitated by
chemical assay of calcium content, in ETD treated mice
at 24 weeks of age was of the same order of magnitude
as in those injected with saline at 12 weeks of age. These
results indicate that ETD administration did not resolve
the mineral deposits that had accumulated in the mice
before the treatment was started at 12 weeks of age as
shown in Set 1. Rather, further mineralization in Set 2 was
arrested at the level that existed at 12 weeks of age but did
not lower the value below the baseline (Figure 2).

Etidronate prevents ectopic mineralization in the
skin
In the first set of experiments, ETD or saline
injections were initiated at 4 weeks of age, a time point
at which no ectopic mineralization is as yet present. At
12 weeks of age, Abcc6-/- mice that had been injected
with saline revealed extensive ectopic mineralization in
the dermal sheath of vibrissae (Figure 1). Injection of
either 0.01× ETD or 0.12× ETD significantly reduced the
degree of mineralization as determined semi-quantitatively
by histopathologic examination (Figure 1) or by direct
quantitative assay of calcium content of the muzzle
skin (Figure 2). Wild type mice on the corresponding
strain background (C57BL/6J) did not develop ectopic
mineralization in the vibrissae (not shown).
www.oncotarget.com

Etidronate modifies the bone microarchitecture
Because ETD possesses both anti-mineralization
and anti-osteoclastic activities, we further evaluated the
morphometric microarchitecture of the trabecular bone
in the ETD treated mice by µCT analysis of their femurs.
Marked differences in the bone density and trabecular
microarchitecture were noted between the male and female
mice, consistent with previous reports [16, 17, 21, 22].
Consequently, sex-matched comparisons of the µCT
results were performed between Abcc6-/- mice and
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Figure 1: Histopathology with Alizarin red stain demonstrates that etidronate treatment prevents, but does not reverse,
ectopic soft tissue mineralization in Abcc6-/- mice. The Abcc6-/- mice develop ectopic mineralization of the dermal sheath of vibrissae
prior to 12 weeks of age, and this process progresses to 24 weeks of age. Subcutaneous injection of etidronate at 0.01× and 0.12× doses
during 4–12 weeks markedly reduced the degree of mineralization in the dermal sheath of vibrissae, when compared to age-matched Abcc6-/mice receiving saline injections (left 3 panels). Etidronate treatment from 12 to 24 weeks of age prevented further mineralization but did not
reverse mineralization that had developed prior to 12 weeks of age (right 3 panels). ETD, etidronate; KO, knockout. Scale bar = 400 µm.

Figure 2: Etidronate treatment prevents vibrissae mineralization as determined by the direct chemical assay of
calcium. Note the significantly elevated calcium content in the muzzle skin of Abcc6-/- mice, either NT or injected with saline, as

compared with the WT mice (right panel). Injections of Abcc6-/- mice subcutaneously with 0.01× and 0.12× ETD significantly reduced the
calcium content of the muzzle skin as compared with age-matched mice injected with saline. Etidronate treated Abcc6-/- mice at 24 weeks
of age demonstrated mineralization similar to Abcc6-/- mice at 12 weeks of age, indicating that ETD prevents further mineralization but
does not reverse mineralization that had developed before initiation of treatment. *p < 0.05, **p < 0.01, compared to KO mice at 12 weeks
of age; ++p < 0.01, compared to KO mice at 24 weeks of age. Mean ± SE; n = 7–10 mice per group. ETD, etidronate; KO, knockout; WT,
wild type; NT, not treated.
www.oncotarget.com
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the corresponding wild type mice on the same strain
background as well as with mice treated with 0.01× or
0.12× ETD in both sets of experiments. No significant
differences in the bone microarchitecture between the
Abcc6-/- mice and the corresponding, sex-matched wild type
mice were noted (Table 2). However, treatment of the mice
with ETD resulted in marked increase in the bone mass
(Figure 3). These changes of bone microarchitecture were
quantified using manufacturer-provided software (Table 2).
In treated mice, the distal femoral bone volume fraction
(BV/TV, %) was increased, corresponding to the increased
trabecular bone mineral density (BMD). ETD treatment
also caused increased trabecular number (Tb.N), decreased
trabecular separation (Tb.Sp), decreased structure model
index (SMI) and connectivity density (Conn.D). These
results attest to the potency of ETD in anti-osteoclastic
activities directed at bone.

three conditions resides within a pathway involved in
generation of PPi and Pi, the mutations in classic PXE
being in ABCC6, in GACI in ENPP1, and in ACDC in
NT5E (Figure 4) [1, 26]. Thus, the unifying pathogenetic
feature of these conditions is reduced plasma PPi/Pi ratio
which allows ectopic mineralization in peripheral tissues
to ensue [1, 9, 23, 25].
A number of spontaneous and genetically engineered
mutant mice have been characterized with ectopic
mineralization of soft connective tissues in the skin and
vascular connective tissues, and many of them recapitulate
features of PXE, GACI and ACDC, respectively [26, 27].
In a particular, the Abcc6-/- mouse serves as an appropriate
model for PXE, characterized by late-onset mineralization
of skin, eyes, and the arterial blood vessels [18, 28].
Examination of these mice by energy dispersive X-ray
and Fourier transform infrared imaging spectroscopy
(FT-IRIS) indicated that the principal components of the
mineral deposits in tissues are calcium and phosphate,
and the Ca/P ratio increases in samples with progressive
mineralization reaching a value of close to 2:1, comparable
to that in endochondral bone [29]. Progressively increasing
mineralization is also reflected by increased mineral-tomatrix ratio, and the determination of the mineralization
process by FT-IRIS suggested progressive maturation of
the mineral deposits from amorphous calcium phosphate
to hydroxyapatite [29]. In this study, we utilized Abcc6-/mice as a model for PXE to test the potential efficacy of
ETD, a stable PPi analog. Bisphosphonates, such as ETD,
can prevent ectopic mineralization by incorporation into
calcium hydroxyapatite mineral crystals preventing their
growth [30].
There is no specific or effective treatment for PXE,
and previous clinical trials attempting to counteract the
mineralization process, such as increasing the magnesium
content of the diet or feeding phosphate binders, have

DISCUSSION
PXE, a prototype of heritable ectopic mineralization
disorders, manifests with progressive deposition of
calcium hydroxyapatite crystals in soft connective
tissues, particularly in the skin and the cardiovascular
system. The disease is of late-onset, and the average age
at diagnosis is in early teens, although in some patients
the diagnosis is not reached until in their late thirties or
forties [1, 2]. GACI is clinically overlapping, yet more
severe, ectopic mineralization disorder, the majority of
patients dying from cardiovascular complications during
their first year of life [23, 24]. Another, recently described
ectopic mineralization disorder is arterial calcification
due to CD73 deficiency (ACDC) which manifests with
late-onset of mineralization affecting primarily the arterial
blood vessels in the lower extremities and the periarticular
ligaments and tendons [25]. The genetic basis of these

Figure 3: Etidronate treatment of Abcc6-/- mice results in altered femur microarchitecture. Note the distinct difference
between male (upper panel) and female (lower panel) mice, assessed by µCT scan. Treatment with etidronate caused changes in femur
microarchitecture, as quantitatively detailed in Table 2. Three males and 3 females were examined in each group with similar findings.
ETD, etidronate; KO, knockout; WT, wild type; NT, not treated.
www.oncotarget.com
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Table 2: Trabecular bone phenotypes by microCT of the right distal femur of the mice*

BV/TV
Tb.Th
Tb.N
Tb.Sp (µm)
SMI
Group,
BMD
Conn.D
Sex
(%)
(µm)
(1/mm)
injected with
(mg/cm3)
(TV/mm3)
Prevention Study (Set 1):
KO, saline
M
988.1 ± 8.2
8.9 ± 1.1
33.6 ± 1.9 4.7 ± 0.1
207.5 ± 7.2
2.3 ± 0.2
222.6 ± 34.7
KO, saline
F
963.4 ± 5.2
5.2 ± 0.4
29.7 ± 0.2 4.0 ± 0.1
246.4 ± 3.0
2.7 ± 0.1
124.0 ± 30.4
+
+
KO, 0.01× ETD M 1064.5 ± 30.9
9.8 ± 1.3
34.1 ± 0.6 5.3 ± 0.1
212.1 ± 18.0 2.1 ± 0.1
250.7 ± 46.5
KO, 0.01× ETD
F
999.5 ± 7.1+ 10.2 ± 1.2+ 33.3 ± 1.5 4.9 ± 0.3+ 197.3 ± 12.3+ 2.0 ± 0.2+ 282.5 ± 37.9+
KO, 0.12× ETD M
1023.4 ± 1.8+ 18.0 ± 1.5++ 36.5 ± 0.7 6.0 ± 0.2++ 156.6 ± 6.9++ 1.1 ± 0.2+ 402.0 ± 28.0+
KO, 0.12× ETD
F 1146.6 ± 67.0+ 15.1 ± 1.6++ 34.4 ± 1.2+ 5.5 ± 0.5+ 177.5 ± 16.2+ 1.4 ± 0.2++ 400.6 ± 73.9+
Reversal Study (Set 2):
KO, saline
M
993.1 ± 7.5
8.7 ± 1.2
35.2 ± 2.5 4.3 ± 0.1
224.9 ± 3.8
2.1 ± 0.2
169.5 ± 13.8
KO, saline
F
981.0 ± 2.6
3.4 ± 0.3
33.7 ± 1.1 2.9 ± 0.1 345.2 ± 10.0 2.9 ± 0.1
53.6 ± 8.5
KO, NT
M
994.4 ± 9.2
12.8 ± 3.4 41.6 ± 5.0 4.4 ± 0.2 219.0 ± 13.0 1.7 ± 0.3
166.1 ± 8.4
KO, NT
F
988.0 ± 11.2
4.2 ± 0.5
32.7 ± 1.2 3.2 ± 0.1 316.7 ± 12.5 2.5 ± 0.1
81.1 ± 8.4
KO, 0.12× ETD M 1033.2 ± 10.5+ 20.4 ± 2.7 44.6 ± 1.1 5.2 ± 0.3 184.1 ± 13.3 0.8 ± 0.2
220.4 ± 16.3+
KO, 0.12× ETD
F
982.1 ± 11.3 12.5 ± 1.2++ 38.9 ± 1.4+ 3.9 ± 0.1++ 250.3 ± 6.1++ 1.3 ± 0.1++ 167.5 ± 11.5++
WT, NT
M 1003.8 ± 10.2 13.6 ± 0.1 48.2 ± 1.0 4.2 ± 0.2
226.2 ± 8.8
1.7 ± 0.2
140.2 ± 11.8
WT, NT
F
1003.3 ± 1.6
3.8 ± 0.8
34.8 ± 0.4 3.0 ± 0.2 335.0 ± 19.8 2.8 ± 0.1
59.5 ± 17.9
*
For a description of different groups, see Table 1. Values are expressed as mean ± SE (three mice of each sex per group).
Statistical significance in comparison to age-matched untreated KO mice of the same sex is indicated: +p < 0.05, ++p < 0.01.
BMD, bone mineral density (mg/cm3); BV/TV, relative bone volume (%); Tb.Th, trabecular thickness (µm); Tb.N, trabecular
number (1/mm); Tb.Sp, trabecular separation (marrow thickness, µm); SMI, structure model index; Conn.D, connectivity
density (TV/mm3). ETD, etidronate; M, male; F, female; NT, not treated.

Figure 4: The PPi and Pi generating pathway points to the critical role of components of the pro-mineralization/antimineralization network. Mutations in the ABCC6, ENPP1, and NT5E genes cause pseudoxanthoma elasticum (PXE), generalized
arterial calcification of infancy (GACI), and arterial calcification due to CD73 deficiency (ACDC), respectively. ABCC6, a putative
transmembrane transporter, mediates ATP release from hepatocytes to extracellular space where ATP is converted to PPi and AMP by
ENPP1, a membrane-bound pyrophosphatase/phosphodiesterase. CD73 converts AMP to Pi and adenosine, the latter one being an inhibitor
of tissue nonspecific alkaline phosphatase (TNAP), an extracellular, yet membrane-bound protein, that hydrolyze PPi to Pi. PPi is an antimineralization factor, and Pi is a pro-mineralization factor. Deficiencies in ABCC6, ENPP1 and CD73 proteins lead to reduced plasma PPi
levels and PPi/Pi ratio, thereby promoting mineralization in peripheral tissues. EC, extracellular; IC, intracellular.
www.oncotarget.com
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highlighted the challenges of the trials in these patients
with slowly progressing and unpredictable clinical
progression [31, 32]. Such clinical trials are further
complicated by considerable phenotypic, both intra- and
inter-familial, variability which may be compounded
by modifying genetic factors and life style variables,
such as diet and exercise [33]. In this study, we have
specifically tested the potential of ETD as a treatment of
PXE under carefully controlled laboratory conditions on a
genetically defined mouse strain background. Our results
demonstrated that ETD, at the dosages used was able to
prevent ectopic mineralization in mice when started before
the onset of the mineralization process, as demonstrated by
our Prevention Study. However, once the mineral deposits
had accumulated in soft connective tissue, ETD did not
reverse the extent of mineralization but arrested further
deposition of mineral at the point when the treatment was
initiated. These observations would imply that if ETD is
to be used to treat patients with PXE, it is ideally started as
soon as the diagnosis has been established. In this regard,
a pre-symptomatic mutation analysis can establish the
diagnosis of PXE in asymptomatic patients in families
with previous history of PXE [34]. Therefore, one would
recommend that all siblings, particularly younger ones,
of patients diagnosed with PXE should be examined for
ABCC6 mutations to establish their genotypic status.
Because ETD has previously shown to be effective
for treatment of disorders characterized by loss of bone
mass, such as osteoporosis and osteogenesis imperfecta
but also bone destruction by cancer metastases [15, 35],
we determined the morphometric characteristics of bones
in PXE mice with and without treatment with ETD.
The results demonstrated that untreated PXE mice, at
least up to 24 weeks of age, did not show differences in
bone morphology as compared with wild type control
mice of the same genetic strain background. Whether
such findings are applicable to PXE patients as well
remains to be determined by bone scanning analyses in
patients. Treatment of Abcc6-/- mice with ETD resulted in
significant increases in bone mass, as determined by µCT.
These results indicated that ETD in dosages used in our
study was effective in modifying the bone density, and
they also suggested that ETD could potentially have dual
beneficial effects in patients with PXE both by preventing
ectopic mineralization and increasing bone mass as part of
prevention of osteoporosis.
Recently (May, 2015), a clinical trial for treatment
of ectopic mineralization in PXE was registered in the
Netherland’s Trial Registry (NTR5180; http://www.
trialregister.nl/trialreg/admin/rctview.asp?TC=5180).
This randomized, double-blinded and placebo controlled
study proposes to test the efficacy of ETD (20 mg/kg
per day) cycling for 2 weeks on and 10 weeks off for 12
months compared with placebo. The primary end point
is the degree of mineralization in the leg arteries after
12 months of treatment as measured by 18F-NaF uptake.
www.oncotarget.com

Secondary objectives include the effects of ETD therapy
on calcium scores of the peripheral arteries, attenuation of
ongoing calcification in other arteries than leg arteries, and
ophthalmological and dermatological changes. Based on our
preclinical mouse studies reported here, one would predict
that ETD in this clinical study will attenuate the progression
of mineralization but does not reverse the existing level of
mineralization with accompanied clinical manifestations.
This prediction is based on the assumption that the efficacy,
pharmacokinetics, and metabolism of ETD are similar in
mice and humans. Indeed, it will be interesting to see whether
ETD treatment in this clinical trial will show beneficial
effects to patients with PXE. These clinical trials should also
consider the established risks associated with bisphosphonate
treatment, such as bone pain or tenderness, osteonecrosis
and bone fractures [36]. Prolonged continued treatment
has also been reported to cause nephrotic syndrome. In
addition to PXE, a study on a case series of patients with
GACI suggested that bisphosphonate treatment of newborns
with this disease was associated with the survival beyond
infancy, although the precise mechanism of this effect
was not established [12]. Finally, a clinical trial proposes
to treat patients with ACDC with ETD (NCT01585402;
https://clinicaltrials.gov/show/NCT01585402) and is
currently recruiting participants. Thus, all these conditions
of ectopic mineralization presenting with reduced PPi/
Pi ratio may be candidates for bisphosphonate treatments,
particularly ETD, to counteract the clinical manifestations.
Finally, it should be noted that other approaches to increase
the PPi/Pi ratio in patients with ectopic mineralization
disorders should be considered, including increased
release of ATP to the extracellular milieau, enhancement of
ENPP1 activity [37], and inhibition of tissue non-specific
alkaline phosphatase (TNAP) [38] (see Figure 4), towards
development of molecularly designed pharmacologic agents
with anti-mineralization potential.

MATERIALS AND METHODS
Mice
The Abcc6tm1JfK mouse was developed by targeted
ablation of the Abcc6 gene (this mouse is referred to as
Abcc6-/-) [18]. The Abcc6 null allele was backcrossed for ten
generations into the C57BL/6J strain to create a congenic
strain (B6.Cg). Abcc6 wild type (Abcc6+/+) and knockout
(Abcc6-/-) mice were generated from heterozygous breeding.
Mice were fed a standard rodent diet (Lab Diet 5010; PMI
Nutrition, Brentwood, MO, USA) with free access to water.
Mice were maintained in the Animal Facility of Thomas
Jefferson University in a temperature- and humiditycontrolled environment. All protocols were approved
by the Institutional Animal Care and Use Committee of
Thomas Jefferson University. Proper handling and care
were practiced according to the animal welfare policies of
the United States Public Health Service.
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Experimental design and treatment

Statistical analysis

WT and Abcc6-/- mice were placed on the standard
rodent diet throughout the experiment. Mice were injected
with saline or etidronate (ETD) subcutaneously, twice a
week. Mice were divided into four groups: (i) mice were
not treated; mice were injected with (ii) sterile saline,
(iii) 0.01× ETD, or (iv) 0.12× ETD. The 1× dose was
calculated to be equivalent to that used for the treatment
of humans for osteoporosis (8 mg/kg/day orally). The
dose of 0.01× ETD was based on the assumption of 1% of
intestinal absorption of ETD, whereas 100% absorption by
subcutaneous injection [13, 14, 39]. Mice were assigned
into the Prevention Study (Set 1) and the Reversal Study
(Set 2) groups with appropriate controls. The groups
of mice in the two sets, characterized by genotype and
treatment, are described in Table 1. In Set 1, Abcc6-/- mice
were injected with ETD beginning at 4 weeks of age for
a total of 8 weeks, 7–10 mice per group. All mice were
euthanized at 12 weeks of age for tissue analysis. In Set
2, Abcc6-/- mice were injected with ETD beginning at
12 weeks of age for a total of 12 weeks, 10 mice per group,
and were euthanized at 24 weeks of age for tissue analysis.

We performed comparisons between different groups
of mice using the 2-sided Kruskal–Wallis nonparametric
test. Statistical significance was reached with p < 0.05.
All statistical computations were completed using SPSS
version 15.0 software (SPSS Inc., Chicago, IL).

Abbreviations
PXE,
pseudoxanthoma
elasticum;
GACI,
generalized arterial calcification of infancy; ETD,
etidronate; AST, alendronate; KO, knockout; WT,
wild type; PPi, inorganic pyrophosphate; Pi, inorganic
phosphate; NT, not treated.
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